相关实验视频
Updated: Jan 13, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.3K
传统化疗引起的心脏毒性:机制和缓解策略
Jiahui Luo1,2, Jiyan Su3,4, Chenglai Xia5,6
1The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, 528000, China.
Apoptosis : an international journal on programmed cell death
|January 10, 2026
概括
化疗可以通过氧化应激和炎症引起心脏损伤 (心脏毒性). 目前的监测和治疗方法有希望,但需要更强大的临床证据才能有效管理.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
背景情况:
- 化疗剂是癌症治疗的重要药物,但会引起严重的毒性.
- 化疗引起的心脏毒性是一个日益严重的临床问题,其发病率越来越高.
- 病变发生涉及氧化应激,编程细胞死亡和炎症途径.
研究的目的:
- 审查目前对化疗诱导心脏毒性的理解.
- 评估现有的监测生物标志物和治疗干预措施.
- 突出局限性和进一步研究的需要.
主要方法:
- 关于化疗诱导心脏毒性研究的文献综述.
- 对心肌损伤,炎症和外体细胞的生物标志物的分析.
- 检查治疗策略,包括ACE抑制剂,德克斯拉松和β-阻断剂.
主要成果:
- 心脏毒性机制包括氧化应激和炎症.
- 生物标志物,如热波宁,IL-6和外体微RNA被用于监测.
- 诸如ACE抑制剂和德克斯拉松等干预措施显示出潜在的益处.
结论:
- 为了更好地了解和管理心脏毒性,进一步的研究是必不可少的.
- 需要大规模的前性研究来验证生物标志物和疗法.
- 优化患者的治疗结果需要加强监测和治疗策略.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
591
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
591
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909

